[{"id":"48bd9dcf-d292-48b2-a409-af70759d67b7","acronym":"Brightline-4","url":"https://clinicaltrials.gov/study/NCT06058793","created_at":"2023-09-28T14:10:28.336Z","updated_at":"2025-02-25T15:20:51.763Z","phase":"Phase 3","brief_title":"Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT06058793 - Brightline-4","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 07/07/2025","primary_completion_date":" 07/07/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2025-02-10"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"ed857d81-c1db-430d-8754-fe70af84d781","acronym":"STRASS 2","url":"https://clinicaltrials.gov/study/NCT04031677","created_at":"2021-01-18T19:47:11.156Z","updated_at":"2025-02-25T17:24:14.778Z","phase":"Phase 3","brief_title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","source_id_and_acronym":"NCT04031677 - STRASS 2","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2028","study_completion_date":" 04/21/2028","last_update_posted":"2025-01-31"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"9059f5a8-2395-4548-8c8d-e5dd82620a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836571","created_at":"2023-11-13T21:15:12.751Z","updated_at":"2024-07-02T16:34:37.937Z","phase":"Phase 2","brief_title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People \u003e= 18 Years Old With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT05836571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD68","pipe":"","alterations":" ","tags":["TMB • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 66","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2024-06-05"},{"id":"89a914ac-06d5-4cf1-bba9-6ccd8e3df332","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083883","created_at":"2023-10-16T16:13:47.307Z","updated_at":"2024-07-02T16:34:59.004Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","source_id_and_acronym":"NCT06083883","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B • SSX1","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2024-06-04"},{"id":"4495832a-2153-4225-9985-32a8ffb570e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06436846","created_at":"2024-05-31T20:35:33.470Z","updated_at":"2024-07-02T16:34:59.819Z","phase":"","brief_title":"Genomic Risk in Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06436846","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MDM2","pipe":"","alterations":" ","tags":["MDM2"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-31"},{"id":"bec56339-c58d-4adf-b9c5-7c33103ad8b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694871","created_at":"2023-01-23T14:59:43.962Z","updated_at":"2024-07-02T16:35:01.360Z","phase":"Phase 2","brief_title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05694871","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • RB1 • CDK4","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-23"},{"id":"8945fb8d-c675-4151-861b-f34bbc81d66c","acronym":"Brightline-1","url":"https://clinicaltrials.gov/study/NCT05218499","created_at":"2022-02-05T18:28:26.477Z","updated_at":"2024-07-02T16:35:02.156Z","phase":"Phase 2/3","brief_title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05218499 - Brightline-1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/16/2024","primary_completion_date":" 04/16/2024","study_txt":" Completion: 05/27/2026","study_completion_date":" 05/27/2026","last_update_posted":"2024-05-22"},{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"},{"id":"ab53141c-faa5-4818-bfa6-8bc2baf852f9","acronym":"DOSa","url":"https://clinicaltrials.gov/study/NCT04668300","created_at":"2024-04-15T18:24:09.850Z","updated_at":"2024-07-02T16:35:09.706Z","phase":"Phase 2","brief_title":"Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma","source_id_and_acronym":"NCT04668300 - DOSa","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD73 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD8 • PD-1 • CD73 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-15"},{"id":"cb96adf5-8ef2-4aba-9494-0926838dbfe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923778","created_at":"2023-12-07T00:15:50.855Z","updated_at":"2024-07-02T16:35:16.265Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT02923778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"4317ceb2-4fba-4c3e-9e3a-12523bffaa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132922","created_at":"2021-01-18T15:26:11.009Z","updated_at":"2024-07-02T16:35:22.736Z","phase":"Phase 1","brief_title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","source_id_and_acronym":"NCT03132922","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 12/27/2022","primary_completion_date":" 12/27/2022","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-01-22"},{"id":"c57ea625-cd33-4c56-acff-cfd618294813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05492682","created_at":"2022-08-08T11:56:49.629Z","updated_at":"2024-07-02T16:35:23.644Z","phase":"Phase 1","brief_title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","source_id_and_acronym":"NCT05492682","lead_sponsor":"Valo Therapeutics Oy","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/02/2023","start_date":" 02/02/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-01-12"},{"id":"159f03cc-8156-48bf-876e-731616d2716a","acronym":"DUET-1","url":"https://clinicaltrials.gov/study/NCT05120271","created_at":"2021-11-15T12:53:36.567Z","updated_at":"2024-07-02T16:35:23.821Z","phase":"Phase 1/2","brief_title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","source_id_and_acronym":"NCT05120271 - DUET-1","lead_sponsor":"Sotio Biotech Inc.","biomarkers":" EGFR • ALK • BRCA • GPC3","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression","tags":["EGFR • ALK • BRCA • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BOXR1030"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 12/01/2041","study_completion_date":" 12/01/2041","last_update_posted":"2024-01-11"},{"id":"a010e6ed-344f-428e-a888-60e487dd1787","acronym":"SALA-002-EW16","url":"https://clinicaltrials.gov/study/NCT03600649","created_at":"2021-04-14T16:53:42.104Z","updated_at":"2024-07-02T16:35:28.552Z","phase":"Phase 1","brief_title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","source_id_and_acronym":"NCT03600649 - SALA-002-EW16","lead_sponsor":"Salarius Pharmaceuticals, LLC","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • seclidemstat (SP2577)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-21"},{"id":"671af31b-ea72-43a1-a698-3450cef359b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905341","created_at":"2023-06-15T17:08:34.937Z","updated_at":"2024-07-02T16:35:29.986Z","phase":"Phase 1","brief_title":"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.","source_id_and_acronym":"NCT05905341","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • PF-07224826"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 04/14/2026","primary_completion_date":" 04/14/2026","study_txt":" Completion: 04/13/2028","study_completion_date":" 04/13/2028","last_update_posted":"2023-11-08"},{"id":"4f2312eb-796b-4bc0-b672-f5373ded6b38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094804","created_at":"2021-10-26T20:53:14.264Z","updated_at":"2024-07-02T16:35:30.540Z","phase":"Phase 1/2","brief_title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","source_id_and_acronym":"NCT05094804","lead_sponsor":"OncoResponse, Inc.","biomarkers":" EGFR • PD-L1 • BRAF • ALK • NTRK","pipe":" | ","alterations":" EGFR mutation • BRCA mutation","tags":["EGFR • PD-L1 • BRAF • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • Libtayo (cemiplimab-rwlc) • OR2805"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2023-11-02"},{"id":"0ed959af-c2b5-458e-b542-28311d0168e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063632","created_at":"2021-01-18T15:05:12.923Z","updated_at":"2024-07-02T16:35:31.715Z","phase":"Phase 2","brief_title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","source_id_and_acronym":"NCT03063632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["IFNG • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-10-25"},{"id":"78651124-78eb-4c6a-8683-68d5a58f336d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02500797","created_at":"2021-01-18T12:03:55.384Z","updated_at":"2024-07-02T16:35:33.299Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02500797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTLA4","pipe":"","alterations":" ","tags":["PD-L1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 08/13/2015","start_date":" 08/13/2015","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2023-10-17"},{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"ee94b79f-8da0-407f-bc94-ca8110bf7bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103631","created_at":"2021-11-02T17:57:08.812Z","updated_at":"2024-07-02T16:35:39.256Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors","source_id_and_acronym":"NCT05103631","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/17/2021","start_date":" 06/17/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2039","study_completion_date":" 12/01/2039","last_update_posted":"2023-08-23"}]